The year's new drugs and biologics 2019.

Abstract

Highlights of our annual review of new approvals and launches on global drug markets include the approval and launch of Trikafta, the most widely applicable treatment to date for cystic fibrosis; approval of the first Ebola vaccine for general (rather than emergency) use; the pilot rollout in three African countries of the world's first malaria vaccine; approval of a new treatment option for multidrug-resistant bacterial infections; and the approval and launch in China of the first new drug to treat Alzheimer's disease in more than a decade. Several new immune checkpoint inhibitors and antibody-drug conjugates were approved for cancer indications, confirming continued industry enthusiasm for cancer immunotherapy. The most notable trend of 2019 was the granting by the Food and Drug Administration (FDA) of a record number of accelerated approvals, many of which were issued several months ahead of the expected action date.

• Authors: A I Graul, P Pina, M Tracy, L Sorbera
• Journal: Drugs of today (Barcelona, Spain : 1998) (Drugs Today (Barc)) Vol. 56 Issue 1 Pg. 47-103 (Jan 2020) ISSN: 1699-3993 [Print] Spain
• PMID: 32055805 (Publication Type: Journal Article)
• Copyright: Copyright 2020 Clarivate Analytics.

Chemical References

• Antineoplastic Agents
• Biological Products
• Ebola Vaccines
• Malaria Vaccines

Topics

• Alzheimer Disease (drug therapy)
• Antineoplastic Agents
• Biological Products
• China
• Drug Approval
• Ebola Vaccines
• Hemorrhagic Fever, Ebola (prevention & control)
• Humans
• Immunotherapy
• Malaria Vaccines
• Neoplasms (drug therapy)
• United States
• United States Food and Drug Administration